Trial Profile
A retrospective study to evaluate the efficacy and safety of ranibizumab in patients with neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Apr 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Novartis
- 19 Apr 2016 New trial record